Displaying 587 (all) recruiting clinical trials.
-
A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas Cutaneous Squamous Cell Carcinoma Merkel Cell Carcinoma and Other Rare Skin Tumors
The purpose of the study is to determine the safety and efficacy of talimogene laherparepvec monotherapy followed by combination therapy with nivolumab (NIVO) for patients ...Phase
Interventional
-
MULTICENTER PHASE II NEOADJUVANT AND ADJUVANT STUDY OF ALECTINIB ENTRECTINIB OR VEMURAFENIB PLUS COBIMETINIB IN PATIENTS WITH STAGES I-III NON-SMALL CELL LUNG CANCER WITH ALK ROS1 NTRK OR BRAF V600E MOLECULAR ALTERATIONS
The purpose of the trial is to determine the efficacy and safety of drugs in patients with untreated non-small cell lung cancer (NSCLC) tumors. In ...Phase
Interventional
-
An Observational Longitudinal Oligo-Center Study to Define Clinical Biofluid Imaging and Digital Outcome Measures in Multiple System Atrophy
This research study is an observational, non-interventional, study to define changes in clinical, neurological, blood, spinal fluid, and neuroimaging (MRI) biomarkers (A biomarker is a ...Phase N/A
Non-Interventional
-
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
The purpose of the study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia ...Phase
Interventional
-
Site for EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
The purpose of the study is to determine the safety and tolerability of pre-operative therapy with 12 weeks of taxane, trastuzumab (or FDA approved biosimilar ...Phase
Interventional
-
A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS
The purpose of the study to determine the safety of CYT-0851 in patients with relapsed/refractory B-Cell malignancies and advanced solid tumors. The study drug ...Phase
Interventional
-
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors
The purpose of the study is to determine the overall response rates as well as safety and tolerability of olaparib in subjects with recurrent/progressive ...Phase
Interventional
-
Early Access Program with Arimoclomol for the Treatment of Niemann-Pick disease Type C in the US
Niemann-Pick disease type C (NPC) is a rare, progressive and debilitating neurodegenerative disease arising from mutations in the NPC1 or NPC2 genes, encoding lysosomal proteins ...Phase N/A Interventional
-
A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
The purpose of the study is to determine the side effects and best dose of anetumab ravtansine when given together with nivolumab, ipilimumab and gemcitabine ...Phase
Interventional
-
A Phase 2 Study of BIO 300 in Patients with COVID-19
COVID-19 is caused by a virus that triggers inflammation of the lungs. This inflammation may damage the lungs and lead to scarring. This scarring causes ...Phase
Interventional
